

### medicare



## Paroxysmal nocturnal haemoglobinuria – eculizumab or ravulizumab – continuing authority application

### **Online PBS Authorities**

You do not need to complete this form if you use the  ${\bf Online\ PBS\ Authorities\ }$  system.

For more information and how to access the **Online PBS Authorities** system, go to **servicesaustralia.gov.au/hppbsauthorities** 

### When to use this form

Use this form to apply for **continuing** PBS-subsidised eculizumab or ravulizumab for patients with paroxysmal nocturnal haemoglobinuria (PNH).

### **Important information**

**Continuing** authority applications can be made using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for PNH **continuing** authority applications.

Complement 5 (C5) inhibitors are defined as eculizumab or ravulizumab.

The information in this form is correct at the time of publishing and may be subject to change.

### **Continuing treatment**

This form is ONLY for **continuing** treatment.

## Section 100 arrangements for eculizumab and ravulizumab

These items are available to a patient who is attending:

- an approved private hospital, or
- a public hospital

#### and is a:

- day admitted patient
- non-admitted patient, or
- patient on discharge.

These items are not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

### For more information

Go to servicesaustralia.gov.au/healthprofessionals

PB328.2412 **1 of 3** 



### medicare



# Paroxysmal nocturnal haemoglobinuria – eculizumab or ravulizumab – continuing authority application

### **Online PBS Authorities** You do not need to complete this form if you use the Online PBS Authorities system. Go to servicesaustralia.gov.au/hppbsauthorities Patient's details Medicare card number Department of Veterans' Affairs card number Mrs | Miss | Ms Family name First given name 3 Date of birth (DD MM YYYY) Patient's current weight Prescriber's details 5 Prescriber number \_\_ Miss \_\_ Ms \_\_ Mr Mrs Family name First given name 7 Business phone number (including area code) Alternative phone number (including area code)

Hospital details	
8	Hospital name
	This hospital is a:
	public hospital
	private hospital
9	Hospital provider number
Conditions and criteria	
	qualify for PBS authority approval, the following conditions ust be met.
10	The patient is being treated by a:
	haematologist
	non-specialist medical physician who has consulted a haematologist
11	This application is for:
	the first continuing treatment with
	eculizumab • Go to 12
	or
	☐ ravulizumab
	subsequent continuing treatment with
	eculizumab Go to 15
	or
	☐ ravulizumab
12	Has the patient received PBS-subsidised treatment with this drug for this condition under the 'Initial', 'Balance of Supply', or 'Grandfather' treatment criteria?  Yes  Go to 14  No
13	Has the patient received PBS-subsidised treatment with this drug for this condition under the 'Initial' or 'Grandfather' treatment restriction?  Yes  No



MCA0PB328 2412

**Privacy notice** Test Result Date of test (DD MM YYYY) **20** Personal information is protected by law (including the Haemoglobin (g/L) Privacy Act 1988) and is collected by Services Australia for the purposes of assessing and processing this authority application. Platelets (x10<sup>9</sup>/L) Personal information may be used by Services Australia, or White Cell Count given to other parties where the individual has agreed to this, or  $(x10^{9}/L)$ where it is required or authorised by law (including for the Reticulocytes purpose of research or conducting investigations).  $(x10^{9}/L)$ More information about the way in which Services Australia Neutrophils manages personal information, including our privacy policy, can  $(x10^{9}/\dot{L})$ be found at servicesaustralia.gov.au/privacypolicy Granulocyte clone size (%) Prescriber's declaration Lactate Dehydrogenase You do not need to **sign** the declaration if you complete this form (LDH) using Adobe Acrobat Reader and return this form through Health Upper limit of Professional Online Services (HPOS) at normal (ULN) for servicesaustralia.gov.au/hpos LDH as quoted by the reporting 21 I declare that: laboratory I am aware that this patient must meet the criteria listed in LDH: ULN ratio the current Schedule of Pharmaceutical Benefits to be (in figures, rounded to one eligible for this medicine. decimal place) I have informed the patient that their personal information (including health information) will be disclosed to Services Go to 18 Australia for the purposes of assessing and processing this **15** Has the patient previously received PBS-subsidised treatment authority application. with this drug for this condition under the 'First Continuing I have provided details of the proposed prescription(s) and Treatment' or 'Switch' criteria? the relevant attachments as specified in the Go to 17 Yes Pharmaceutical Benefits Scheme restriction. Nο the information I have provided in this form is complete and correct. **16** Has the patient previously received PBS-subsidised treatment with this drug for this condition under the 'First Continuing I understand that: Treatment' or 'Return' criteria? giving false or misleading information is a serious offence. Yes I have read, understood and agree to the above. No Date (DD MM YYYY) (you must date this declaration) 17 Has the patient experienced clinical improvement or a stabilisation of the condition as a result of treatment with this drug? Prescriber's signature (only required if returning by post) Yes Nο Ø1 18 Is this treatment in combination with another C5 inhibitor or pegcetacoplan? Yes **Returning this form** No Return this form, details of the proposed prescription(s) and any relevant attachments: Checklist online (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos 19 The relevant attachments need to be provided with or this form. by post (signature required) to Details of the proposed prescription(s). Services Australia Complex Drugs Programs Reply Paid 9826 **HOBART TAS 7001** 

4 Provide details of the following monitoring requirements